KLOW 80 MG

Description

KLOW 80mg research peptide blend — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

KLOW is GLOW plus one: the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157, TB-500 — here the 889 Da thymosin β4 fragment, not the whole protein — and KPV, the anti-inflammatory tail of α-MSH studied mostly in mouse gut models^{[1, 2]}. That list comes from the batch report, not from the name. No study has looked at the four together. One vial of lyophilized powder, for laboratory research only.

Full research overview, study table & references → KLOW in Canada: research guide (component guides: GLOW / GHK-Cu · BPC-157 · TB-500)

Identity at a glance

This batch: certificate of analysis

Product tested	KLOW, declared 80 mg (this listing)
Testing laboratory	Janoshik Analytical (independent)
Report number	#172068
Sample received / analysis date	3 June 2026 / 18 June 2026
Components measured	GHK-Cu 40.45 mg · BPC-157 10.73 mg · TB-500 (889 Da) 10.49 mg · KPV 11.08 mg
Purity	Not stated on this report. Identity and per-component quantity only.
Report	View the report image · COA library

The four amounts add up to 72.75 mg against an 80 mg declaration — our arithmetic, printed as found. Match the batch on your label to this report before use; the blend COA guide explains how to read a multi-component document one line at a time.

What researchers have looked at

• KPV, mouse colitis (2008): in drinking water it lowered the incidence of DSS and TNBS colitis and cut cytokine expression, entering cells via the PepT1 transporter^[1]; in a second lab, treated mice recovered weight faster with fewer infiltrates and lower myeloperoxidase, even without a working melanocortin-1 receptor^[2].
• KPV, microbes in vitro (2000): α-MSH and KPV inhibited S. aureus colony formation and C. albicans germ-tube formation, tracking a rise in cAMP^[3].
• GHK-Cu, rat wound chambers (1993): concentration-dependent increases in collagen, glycosaminoglycans, DNA and dry weight^[4]. BPC-157, rat Achilles (2003): higher failure load after transection than saline^[5]. Thymosin β4 motif (2003): the LKKTETQ heptapeptide alone reproduced the parent peptide’s endothelial migration and sprouting activity^[6].
• Limits: the one study pairing BPC-157 with TB-500 (32 rats, 2026) found no added effect from the combination^[7]; a 2025 systematic review of BPC-157 reports no clinical safety data^[8]; nothing tests the four-way blend, and no human study supports any use of KLOW.

Storage and handling

• Keep the sealed vial frozen at −20 °C for long-term storage (the site gives up to 24 months for dry powder); short-term, somewhere cool, dry and dark; do not cycle it through freeze–thaw.
• All four components are water-soluble; the mouse work gave KPV in drinking water^[1] and the rat studies used saline^{[4, 7]}. Bacteriostatic water is stocked separately. Protocols are the researcher’s own.

Related: GLOW 70MG (three components; its TB-500 is full-length thymosin β4) · GHK-CU 100MG · BPC-157 5MG · TB-500 5MG. Canada Post from inside Canada; see the shipping policy for cut-off times and the free-shipping threshold. The full catalogue is on our buy peptides online in Canada page.

Frequently asked questions

Can I buy KLOW 80mg in Canada?

Yes. The vial ships from inside Canada by Canada Post, with no customs hold. It is supplied for laboratory research only; none of its four components has an approved drug product in Canada, the US or the EU.

What does the KLOW batch report actually list?

Janoshik report #172068 (analysis 18 June 2026) reports GHK-Cu 40.45 mg (35.88 mg GHK + 4.57 mg copper), BPC-157 10.73 mg, TB-500 10.49 mg labelled 889 Da (the Ac-LKKTETQ fragment), and KPV 11.08 mg. It gives no purity percentage, so none is quoted here.

What is KPV and why is it in KLOW?

KPV is Lys-Pro-Val, residues 11–13 of α-melanocyte-stimulating hormone. It is the fourth component that distinguishes KLOW from GLOW. Its published research is mainly mouse colitis models, where oral KPV reduced inflammation and was taken into cells by the PepT1 transporter (PMIDs 18061177, 18092346); no human trial of KPV was found.

How should KLOW be stored and handled?

As sealed lyophilized powder at −20 °C for the long term (the site states up to 24 months), cool, dry and dark for short periods, without repeated freeze–thaw. Dissolved, it is a four-analyte sample. No dosing or administration guidance is provided.

Cited

1. Dalmasso et al. (2008), Gastroenterology — PMID 18061177
2. Kannengiesser et al. (2008), Inflammatory bowel diseases — PMID 18092346
3. Cutuli et al. (2000), Journal of leukocyte biology — PMID 10670585
4. Maquart et al. (1993), The Journal of clinical investigation — PMID 8227353
5. Staresinic et al. (2003), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 14554208
6. Philp et al. (2003), FASEB journal : official publication of the Federation of American Societies for Experimental Biology — PMID 14500546
7. Biçer et al. (2026), Joint diseases and related surgery — PMID 42542926
8. Vasireddi et al. (2025), HSS journal : the musculoskeletal journal of Hospital for Special Surgery — PMID 40756949

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.